Stockscreener 앱 받기
13.34
8.19%
-1.19
시간 외 거래:
13.55
0.21
+1.57%
전일 마감가:
$14.53
열려 있는:
$14.8
하루 거래량:
1.04M
Relative Volume:
2.16
시가총액:
$1.71B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+7.41%
1개월 성능:
+4.22%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$13.13
$14.99
1주일 범위
$12.20
$15.21
52주 변동 폭
$11.00
$16.75
Generate Biomedicines Inc Stock (GENB) Company Profile
명칭
Generate Biomedicines Inc
전화
888-469-0055
주소
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.34 | 1.86B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | H.C. Wainwright | Buy |
| 2026-03-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-24 | 개시 | Goldman | Buy |
| 2026-03-24 | 개시 | Guggenheim | Buy |
| 2026-03-24 | 개시 | Morgan Stanley | Overweight |
| 2026-03-24 | 개시 | Piper Sandler | Overweight |
모두보기
Generate Biomedicines Inc 주식(GENB)의 최신 뉴스
This AI biotech stock landed a $10.4 million Nvidia investment - MSN
symbol__ Stock Quote Price and Forecast - CNN
Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer? - simplywall.st
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment - simplywall.st
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment - Yahoo Finance
A Deep Dive Into Nvidia’s Latest Portfolio Moves - Investing.com
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Generate Biomedicines (GENB) News Flow - Moomoo
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - The Chronicle-Journal
Trades UpdateBuying More Generate BiomedicinesDeepDive - Moomoo
AI Protein Design Market 2026-2033 | Market Growth to FY (Q2) - openPR.com
Flagship entities disclose large GENB holdings, Flagship Pioneering holds 48.9% (GENB) - Stock Titan
Generate Biomedicines (NASDAQ: GENB) exec Michael Nally holds 5.2% stake - Stock Titan
GENB : Generate Biomedicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
GENB: Generate Biomedicines, Inc.Brokerage Recommendations Chart - Zacks Investment Research
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Programmable Biology: Will GENB Generate Investor Interest? - RTTNews
Generate Biomedicines, Inc. Stock 12‑Month Price Target Raised to $25.4, Implies 57% Upside - TradingView
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines, Inc. (GENB) Ps Ratio (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Enterprise Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Free Cash Flow (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) - Zacks Investment Research
Dividend HistoryGenerate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Book Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price To Free Cash Flow - Zacks Investment Research
All News for GENB : Generate Biomedicines, Inc. - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price To Cash Flow - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Eps Diluted (TTM) - Zacks Investment Research
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Should I buy Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Net Income (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Expenses (Quarterly) - Zacks Investment Research
What is the current Price Target and Forecast for Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Cash From Operations (TTM) - Zacks Investment Research
Number of shareholders of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB : Generate Biomedicines, Inc. Key Company Details - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Beta - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Dividend (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Long Term Debt (Quarterly) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Gross Margin (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Liabilities - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Cash From Financing (Quarterly) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price Book Value - Zacks Investment Research
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Inc (GENB) 재무 분석
Generate Biomedicines Inc (GENB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):